The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Targeted Drugs for Breast Cancer Market Research Report 2025
Synopsis
The global Targeted Drugs for Breast Cancer market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Targeted Drugs for Breast Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Targeted Drugs for Breast Cancer.
Report Scope
The Targeted Drugs for Breast Cancer market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Targeted Drugs for Breast Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Targeted Drugs for Breast Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Teva
Mylan
Hikma
Hengrui Medicine
Cipla
Reliance Group
Hetero
Pfizer
Eli Lilly
Novartis
CANbridge
Puma Biotechnology
AstraZeneca
Chugai Pharmaceutical
Eisai
GlaxoSmithKline
Bristol-Myers Squibb
Otsuka Pharmaceutical
Merck
BioMarin
Hengrui Pharmaceutical
Beijing Biostar Technologies
Bayer
Segment by Type
HER-2 Targeted Drugs
CDK4/6 Inhibitors
PARP Targeted Drugs
PI3K/AKT/mTor Pathway Inhibitors
ER Targeted Drugs
Aromatase Inhibitors
Tubulin Inhibitors
VEGF Targeted Drugs
YTMS Targeted Drugs
Others
Segment by Application
Hospital
Clinic
Drug Center
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Targeted Drugs for Breast Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Targeted Drugs for Breast Cancer market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Targeted Drugs for Breast Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Targeted Drugs for Breast Cancer.
Report Scope
The Targeted Drugs for Breast Cancer market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Targeted Drugs for Breast Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Targeted Drugs for Breast Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Teva
Mylan
Hikma
Hengrui Medicine
Cipla
Reliance Group
Hetero
Pfizer
Eli Lilly
Novartis
CANbridge
Puma Biotechnology
AstraZeneca
Chugai Pharmaceutical
Eisai
GlaxoSmithKline
Bristol-Myers Squibb
Otsuka Pharmaceutical
Merck
BioMarin
Hengrui Pharmaceutical
Beijing Biostar Technologies
Bayer
Segment by Type
HER-2 Targeted Drugs
CDK4/6 Inhibitors
PARP Targeted Drugs
PI3K/AKT/mTor Pathway Inhibitors
ER Targeted Drugs
Aromatase Inhibitors
Tubulin Inhibitors
VEGF Targeted Drugs
YTMS Targeted Drugs
Others
Segment by Application
Hospital
Clinic
Drug Center
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Targeted Drugs for Breast Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Targeted Drugs for Breast Cancer Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 HER-2 Targeted Drugs
1.2.3 CDK4/6 Inhibitors
1.2.4 PARP Targeted Drugs
1.2.5 PI3K/AKT/mTor Pathway Inhibitors
1.2.6 ER Targeted Drugs
1.2.7 Aromatase Inhibitors
1.2.8 Tubulin Inhibitors
1.2.9 VEGF Targeted Drugs
1.2.10 YTMS Targeted Drugs
1.2.11 Others
1.3 Market by Application
1.3.1 Global Targeted Drugs for Breast Cancer Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Drug Center
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Targeted Drugs for Breast Cancer Market Perspective (2019-2030)
2.2 Targeted Drugs for Breast Cancer Growth Trends by Region
2.2.1 Global Targeted Drugs for Breast Cancer Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Targeted Drugs for Breast Cancer Historic Market Size by Region (2019-2024)
2.2.3 Targeted Drugs for Breast Cancer Forecasted Market Size by Region (2025-2030)
2.3 Targeted Drugs for Breast Cancer Market Dynamics
2.3.1 Targeted Drugs for Breast Cancer Industry Trends
2.3.2 Targeted Drugs for Breast Cancer Market Drivers
2.3.3 Targeted Drugs for Breast Cancer Market Challenges
2.3.4 Targeted Drugs for Breast Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Targeted Drugs for Breast Cancer Players by Revenue
3.1.1 Global Top Targeted Drugs for Breast Cancer Players by Revenue (2019-2024)
3.1.2 Global Targeted Drugs for Breast Cancer Revenue Market Share by Players (2019-2024)
3.2 Global Targeted Drugs for Breast Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Targeted Drugs for Breast Cancer Revenue
3.4 Global Targeted Drugs for Breast Cancer Market Concentration Ratio
3.4.1 Global Targeted Drugs for Breast Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Targeted Drugs for Breast Cancer Revenue in 2023
3.5 Targeted Drugs for Breast Cancer Key Players Head office and Area Served
3.6 Key Players Targeted Drugs for Breast Cancer Product Solution and Service
3.7 Date of Enter into Targeted Drugs for Breast Cancer Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Targeted Drugs for Breast Cancer Breakdown Data by Type
4.1 Global Targeted Drugs for Breast Cancer Historic Market Size by Type (2019-2024)
4.2 Global Targeted Drugs for Breast Cancer Forecasted Market Size by Type (2025-2030)
5 Targeted Drugs for Breast Cancer Breakdown Data by Application
5.1 Global Targeted Drugs for Breast Cancer Historic Market Size by Application (2019-2024)
5.2 Global Targeted Drugs for Breast Cancer Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Targeted Drugs for Breast Cancer Market Size (2019-2030)
6.2 North America Targeted Drugs for Breast Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Targeted Drugs for Breast Cancer Market Size by Country (2019-2024)
6.4 North America Targeted Drugs for Breast Cancer Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Targeted Drugs for Breast Cancer Market Size (2019-2030)
7.2 Europe Targeted Drugs for Breast Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Targeted Drugs for Breast Cancer Market Size by Country (2019-2024)
7.4 Europe Targeted Drugs for Breast Cancer Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Targeted Drugs for Breast Cancer Market Size (2019-2030)
8.2 Asia-Pacific Targeted Drugs for Breast Cancer Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Targeted Drugs for Breast Cancer Market Size by Region (2019-2024)
8.4 Asia-Pacific Targeted Drugs for Breast Cancer Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Targeted Drugs for Breast Cancer Market Size (2019-2030)
9.2 Latin America Targeted Drugs for Breast Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Targeted Drugs for Breast Cancer Market Size by Country (2019-2024)
9.4 Latin America Targeted Drugs for Breast Cancer Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Targeted Drugs for Breast Cancer Market Size (2019-2030)
10.2 Middle East & Africa Targeted Drugs for Breast Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Targeted Drugs for Breast Cancer Market Size by Country (2019-2024)
10.4 Middle East & Africa Targeted Drugs for Breast Cancer Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Targeted Drugs for Breast Cancer Introduction
11.1.4 Roche Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)
11.1.5 Roche Recent Development
11.2 Teva
11.2.1 Teva Company Detail
11.2.2 Teva Business Overview
11.2.3 Teva Targeted Drugs for Breast Cancer Introduction
11.2.4 Teva Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)
11.2.5 Teva Recent Development
11.3 Mylan
11.3.1 Mylan Company Detail
11.3.2 Mylan Business Overview
11.3.3 Mylan Targeted Drugs for Breast Cancer Introduction
11.3.4 Mylan Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)
11.3.5 Mylan Recent Development
11.4 Hikma
11.4.1 Hikma Company Detail
11.4.2 Hikma Business Overview
11.4.3 Hikma Targeted Drugs for Breast Cancer Introduction
11.4.4 Hikma Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)
11.4.5 Hikma Recent Development
11.5 Hengrui Medicine
11.5.1 Hengrui Medicine Company Detail
11.5.2 Hengrui Medicine Business Overview
11.5.3 Hengrui Medicine Targeted Drugs for Breast Cancer Introduction
11.5.4 Hengrui Medicine Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)
11.5.5 Hengrui Medicine Recent Development
11.6 Cipla
11.6.1 Cipla Company Detail
11.6.2 Cipla Business Overview
11.6.3 Cipla Targeted Drugs for Breast Cancer Introduction
11.6.4 Cipla Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)
11.6.5 Cipla Recent Development
11.7 Reliance Group
11.7.1 Reliance Group Company Detail
11.7.2 Reliance Group Business Overview
11.7.3 Reliance Group Targeted Drugs for Breast Cancer Introduction
11.7.4 Reliance Group Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)
11.7.5 Reliance Group Recent Development
11.8 Hetero
11.8.1 Hetero Company Detail
11.8.2 Hetero Business Overview
11.8.3 Hetero Targeted Drugs for Breast Cancer Introduction
11.8.4 Hetero Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)
11.8.5 Hetero Recent Development
11.9 Pfizer
11.9.1 Pfizer Company Detail
11.9.2 Pfizer Business Overview
11.9.3 Pfizer Targeted Drugs for Breast Cancer Introduction
11.9.4 Pfizer Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)
11.9.5 Pfizer Recent Development
11.10 Eli Lilly
11.10.1 Eli Lilly Company Detail
11.10.2 Eli Lilly Business Overview
11.10.3 Eli Lilly Targeted Drugs for Breast Cancer Introduction
11.10.4 Eli Lilly Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)
11.10.5 Eli Lilly Recent Development
11.11 Novartis
11.11.1 Novartis Company Detail
11.11.2 Novartis Business Overview
11.11.3 Novartis Targeted Drugs for Breast Cancer Introduction
11.11.4 Novartis Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)
11.11.5 Novartis Recent Development
11.12 CANbridge
11.12.1 CANbridge Company Detail
11.12.2 CANbridge Business Overview
11.12.3 CANbridge Targeted Drugs for Breast Cancer Introduction
11.12.4 CANbridge Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)
11.12.5 CANbridge Recent Development
11.13 Puma Biotechnology
11.13.1 Puma Biotechnology Company Detail
11.13.2 Puma Biotechnology Business Overview
11.13.3 Puma Biotechnology Targeted Drugs for Breast Cancer Introduction
11.13.4 Puma Biotechnology Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)
11.13.5 Puma Biotechnology Recent Development
11.14 AstraZeneca
11.14.1 AstraZeneca Company Detail
11.14.2 AstraZeneca Business Overview
11.14.3 AstraZeneca Targeted Drugs for Breast Cancer Introduction
11.14.4 AstraZeneca Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)
11.14.5 AstraZeneca Recent Development
11.15 Chugai Pharmaceutical
11.15.1 Chugai Pharmaceutical Company Detail
11.15.2 Chugai Pharmaceutical Business Overview
11.15.3 Chugai Pharmaceutical Targeted Drugs for Breast Cancer Introduction
11.15.4 Chugai Pharmaceutical Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)
11.15.5 Chugai Pharmaceutical Recent Development
11.16 Eisai
11.16.1 Eisai Company Detail
11.16.2 Eisai Business Overview
11.16.3 Eisai Targeted Drugs for Breast Cancer Introduction
11.16.4 Eisai Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)
11.16.5 Eisai Recent Development
11.17 GlaxoSmithKline
11.17.1 GlaxoSmithKline Company Detail
11.17.2 GlaxoSmithKline Business Overview
11.17.3 GlaxoSmithKline Targeted Drugs for Breast Cancer Introduction
11.17.4 GlaxoSmithKline Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)
11.17.5 GlaxoSmithKline Recent Development
11.18 Bristol-Myers Squibb
11.18.1 Bristol-Myers Squibb Company Detail
11.18.2 Bristol-Myers Squibb Business Overview
11.18.3 Bristol-Myers Squibb Targeted Drugs for Breast Cancer Introduction
11.18.4 Bristol-Myers Squibb Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)
11.18.5 Bristol-Myers Squibb Recent Development
11.19 Otsuka Pharmaceutical
11.19.1 Otsuka Pharmaceutical Company Detail
11.19.2 Otsuka Pharmaceutical Business Overview
11.19.3 Otsuka Pharmaceutical Targeted Drugs for Breast Cancer Introduction
11.19.4 Otsuka Pharmaceutical Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)
11.19.5 Otsuka Pharmaceutical Recent Development
11.20 Merck
11.20.1 Merck Company Detail
11.20.2 Merck Business Overview
11.20.3 Merck Targeted Drugs for Breast Cancer Introduction
11.20.4 Merck Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)
11.20.5 Merck Recent Development
11.21 BioMarin
11.21.1 BioMarin Company Detail
11.21.2 BioMarin Business Overview
11.21.3 BioMarin Targeted Drugs for Breast Cancer Introduction
11.21.4 BioMarin Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)
11.21.5 BioMarin Recent Development
11.22 Hengrui Pharmaceutical
11.22.1 Hengrui Pharmaceutical Company Detail
11.22.2 Hengrui Pharmaceutical Business Overview
11.22.3 Hengrui Pharmaceutical Targeted Drugs for Breast Cancer Introduction
11.22.4 Hengrui Pharmaceutical Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)
11.22.5 Hengrui Pharmaceutical Recent Development
11.23 Beijing Biostar Technologies
11.23.1 Beijing Biostar Technologies Company Detail
11.23.2 Beijing Biostar Technologies Business Overview
11.23.3 Beijing Biostar Technologies Targeted Drugs for Breast Cancer Introduction
11.23.4 Beijing Biostar Technologies Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)
11.23.5 Beijing Biostar Technologies Recent Development
11.24 Bayer
11.24.1 Bayer Company Detail
11.24.2 Bayer Business Overview
11.24.3 Bayer Targeted Drugs for Breast Cancer Introduction
11.24.4 Bayer Revenue in Targeted Drugs for Breast Cancer Business (2019-2024)
11.24.5 Bayer Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Targeted Drugs for Breast Cancer Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of HER-2 Targeted Drugs
Table 3. Key Players of CDK4/6 Inhibitors
Table 4. Key Players of PARP Targeted Drugs
Table 5. Key Players of PI3K/AKT/mTor Pathway Inhibitors
Table 6. Key Players of ER Targeted Drugs
Table 7. Key Players of Aromatase Inhibitors
Table 8. Key Players of Tubulin Inhibitors
Table 9. Key Players of VEGF Targeted Drugs
Table 10. Key Players of YTMS Targeted Drugs
Table 11. Key Players of Others
Table 12. Global Targeted Drugs for Breast Cancer Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 13. Global Targeted Drugs for Breast Cancer Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 14. Global Targeted Drugs for Breast Cancer Market Size by Region (2019-2024) & (US$ Million)
Table 15. Global Targeted Drugs for Breast Cancer Market Share by Region (2019-2024)
Table 16. Global Targeted Drugs for Breast Cancer Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 17. Global Targeted Drugs for Breast Cancer Market Share by Region (2025-2030)
Table 18. Targeted Drugs for Breast Cancer Market Trends
Table 19. Targeted Drugs for Breast Cancer Market Drivers
Table 20. Targeted Drugs for Breast Cancer Market Challenges
Table 21. Targeted Drugs for Breast Cancer Market Restraints
Table 22. Global Targeted Drugs for Breast Cancer Revenue by Players (2019-2024) & (US$ Million)
Table 23. Global Targeted Drugs for Breast Cancer Market Share by Players (2019-2024)
Table 24. Global Top Targeted Drugs for Breast Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drugs for Breast Cancer as of 2023)
Table 25. Ranking of Global Top Targeted Drugs for Breast Cancer Companies by Revenue (US$ Million) in 2023
Table 26. Global 5 Largest Players Market Share by Targeted Drugs for Breast Cancer Revenue (CR5 and HHI) & (2019-2024)
Table 27. Key Players Headquarters and Area Served
Table 28. Key Players Targeted Drugs for Breast Cancer Product Solution and Service
Table 29. Date of Enter into Targeted Drugs for Breast Cancer Market
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Targeted Drugs for Breast Cancer Market Size by Type (2019-2024) & (US$ Million)
Table 32. Global Targeted Drugs for Breast Cancer Revenue Market Share by Type (2019-2024)
Table 33. Global Targeted Drugs for Breast Cancer Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 34. Global Targeted Drugs for Breast Cancer Revenue Market Share by Type (2025-2030)
Table 35. Global Targeted Drugs for Breast Cancer Market Size by Application (2019-2024) & (US$ Million)
Table 36. Global Targeted Drugs for Breast Cancer Revenue Market Share by Application (2019-2024)
Table 37. Global Targeted Drugs for Breast Cancer Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 38. Global Targeted Drugs for Breast Cancer Revenue Market Share by Application (2025-2030)
Table 39. North America Targeted Drugs for Breast Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 40. North America Targeted Drugs for Breast Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 41. North America Targeted Drugs for Breast Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 42. Europe Targeted Drugs for Breast Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Europe Targeted Drugs for Breast Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 44. Europe Targeted Drugs for Breast Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 45. Asia-Pacific Targeted Drugs for Breast Cancer Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 46. Asia-Pacific Targeted Drugs for Breast Cancer Market Size by Region (2019-2024) & (US$ Million)
Table 47. Asia-Pacific Targeted Drugs for Breast Cancer Market Size by Region (2025-2030) & (US$ Million)
Table 48. Latin America Targeted Drugs for Breast Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 49. Latin America Targeted Drugs for Breast Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 50. Latin America Targeted Drugs for Breast Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 51. Middle East & Africa Targeted Drugs for Breast Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 52. Middle East & Africa Targeted Drugs for Breast Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 53. Middle East & Africa Targeted Drugs for Breast Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 54. Roche Company Detail
Table 55. Roche Business Overview
Table 56. Roche Targeted Drugs for Breast Cancer Product
Table 57. Roche Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)
Table 58. Roche Recent Development
Table 59. Teva Company Detail
Table 60. Teva Business Overview
Table 61. Teva Targeted Drugs for Breast Cancer Product
Table 62. Teva Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)
Table 63. Teva Recent Development
Table 64. Mylan Company Detail
Table 65. Mylan Business Overview
Table 66. Mylan Targeted Drugs for Breast Cancer Product
Table 67. Mylan Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)
Table 68. Mylan Recent Development
Table 69. Hikma Company Detail
Table 70. Hikma Business Overview
Table 71. Hikma Targeted Drugs for Breast Cancer Product
Table 72. Hikma Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)
Table 73. Hikma Recent Development
Table 74. Hengrui Medicine Company Detail
Table 75. Hengrui Medicine Business Overview
Table 76. Hengrui Medicine Targeted Drugs for Breast Cancer Product
Table 77. Hengrui Medicine Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)
Table 78. Hengrui Medicine Recent Development
Table 79. Cipla Company Detail
Table 80. Cipla Business Overview
Table 81. Cipla Targeted Drugs for Breast Cancer Product
Table 82. Cipla Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)
Table 83. Cipla Recent Development
Table 84. Reliance Group Company Detail
Table 85. Reliance Group Business Overview
Table 86. Reliance Group Targeted Drugs for Breast Cancer Product
Table 87. Reliance Group Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)
Table 88. Reliance Group Recent Development
Table 89. Hetero Company Detail
Table 90. Hetero Business Overview
Table 91. Hetero Targeted Drugs for Breast Cancer Product
Table 92. Hetero Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)
Table 93. Hetero Recent Development
Table 94. Pfizer Company Detail
Table 95. Pfizer Business Overview
Table 96. Pfizer Targeted Drugs for Breast Cancer Product
Table 97. Pfizer Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)
Table 98. Pfizer Recent Development
Table 99. Eli Lilly Company Detail
Table 100. Eli Lilly Business Overview
Table 101. Eli Lilly Targeted Drugs for Breast Cancer Product
Table 102. Eli Lilly Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)
Table 103. Eli Lilly Recent Development
Table 104. Novartis Company Detail
Table 105. Novartis Business Overview
Table 106. Novartis Targeted Drugs for Breast Cancer Product
Table 107. Novartis Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)
Table 108. Novartis Recent Development
Table 109. CANbridge Company Detail
Table 110. CANbridge Business Overview
Table 111. CANbridge Targeted Drugs for Breast Cancer Product
Table 112. CANbridge Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)
Table 113. CANbridge Recent Development
Table 114. Puma Biotechnology Company Detail
Table 115. Puma Biotechnology Business Overview
Table 116. Puma Biotechnology Targeted Drugs for Breast Cancer Product
Table 117. Puma Biotechnology Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)
Table 118. Puma Biotechnology Recent Development
Table 119. AstraZeneca Company Detail
Table 120. AstraZeneca Business Overview
Table 121. AstraZeneca Targeted Drugs for Breast Cancer Product
Table 122. AstraZeneca Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)
Table 123. AstraZeneca Recent Development
Table 124. Chugai Pharmaceutical Company Detail
Table 125. Chugai Pharmaceutical Business Overview
Table 126. Chugai Pharmaceutical Targeted Drugs for Breast Cancer Product
Table 127. Chugai Pharmaceutical Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)
Table 128. Chugai Pharmaceutical Recent Development
Table 129. Eisai Company Detail
Table 130. Eisai Business Overview
Table 131. Eisai Targeted Drugs for Breast Cancer Product
Table 132. Eisai Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)
Table 133. Eisai Recent Development
Table 134. GlaxoSmithKline Company Detail
Table 135. GlaxoSmithKline Business Overview
Table 136. GlaxoSmithKline Targeted Drugs for Breast Cancer Product
Table 137. GlaxoSmithKline Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)
Table 138. GlaxoSmithKline Recent Development
Table 139. Bristol-Myers Squibb Company Detail
Table 140. Bristol-Myers Squibb Business Overview
Table 141. Bristol-Myers Squibb Targeted Drugs for Breast Cancer Product
Table 142. Bristol-Myers Squibb Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)
Table 143. Bristol-Myers Squibb Recent Development
Table 144. Otsuka Pharmaceutical Company Detail
Table 145. Otsuka Pharmaceutical Business Overview
Table 146. Otsuka Pharmaceutical Targeted Drugs for Breast Cancer Product
Table 147. Otsuka Pharmaceutical Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)
Table 148. Otsuka Pharmaceutical Recent Development
Table 149. Merck Company Detail
Table 150. Merck Business Overview
Table 151. Merck Targeted Drugs for Breast Cancer Product
Table 152. Merck Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)
Table 153. Merck Recent Development
Table 154. BioMarin Company Detail
Table 155. BioMarin Business Overview
Table 156. BioMarin Targeted Drugs for Breast Cancer Product
Table 157. BioMarin Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)
Table 158. BioMarin Recent Development
Table 159. Hengrui Pharmaceutical Company Detail
Table 160. Hengrui Pharmaceutical Business Overview
Table 161. Hengrui Pharmaceutical Targeted Drugs for Breast Cancer Product
Table 162. Hengrui Pharmaceutical Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)
Table 163. Hengrui Pharmaceutical Recent Development
Table 164. Beijing Biostar Technologies Company Detail
Table 165. Beijing Biostar Technologies Business Overview
Table 166. Beijing Biostar Technologies Targeted Drugs for Breast Cancer Product
Table 167. Beijing Biostar Technologies Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)
Table 168. Beijing Biostar Technologies Recent Development
Table 169. Bayer Company Detail
Table 170. Bayer Business Overview
Table 171. Bayer Targeted Drugs for Breast Cancer Product
Table 172. Bayer Revenue in Targeted Drugs for Breast Cancer Business (2019-2024) & (US$ Million)
Table 173. Bayer Recent Development
Table 174. Research Programs/Design for This Report
Table 175. Key Data Information from Secondary Sources
Table 176. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Targeted Drugs for Breast Cancer Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Targeted Drugs for Breast Cancer Market Share by Type: 2023 VS 2030
Figure 3. HER-2 Targeted Drugs Features
Figure 4. CDK4/6 Inhibitors Features
Figure 5. PARP Targeted Drugs Features
Figure 6. PI3K/AKT/mTor Pathway Inhibitors Features
Figure 7. ER Targeted Drugs Features
Figure 8. Aromatase Inhibitors Features
Figure 9. Tubulin Inhibitors Features
Figure 10. VEGF Targeted Drugs Features
Figure 11. YTMS Targeted Drugs Features
Figure 12. Others Features
Figure 13. Global Targeted Drugs for Breast Cancer Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 14. Global Targeted Drugs for Breast Cancer Market Share by Application: 2023 VS 2030
Figure 15. Hospital Case Studies
Figure 16. Clinic Case Studies
Figure 17. Drug Center Case Studies
Figure 18. Others Case Studies
Figure 19. Targeted Drugs for Breast Cancer Report Years Considered
Figure 20. Global Targeted Drugs for Breast Cancer Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 21. Global Targeted Drugs for Breast Cancer Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 22. Global Targeted Drugs for Breast Cancer Market Share by Region: 2023 VS 2030
Figure 23. Global Targeted Drugs for Breast Cancer Market Share by Players in 2023
Figure 24. Global Top Targeted Drugs for Breast Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drugs for Breast Cancer as of 2023)
Figure 25. The Top 10 and 5 Players Market Share by Targeted Drugs for Breast Cancer Revenue in 2023
Figure 26. North America Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. North America Targeted Drugs for Breast Cancer Market Share by Country (2019-2030)
Figure 28. United States Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Canada Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Europe Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Europe Targeted Drugs for Breast Cancer Market Share by Country (2019-2030)
Figure 32. Germany Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. France Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. U.K. Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Italy Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Russia Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Nordic Countries Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Asia-Pacific Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Asia-Pacific Targeted Drugs for Breast Cancer Market Share by Region (2019-2030)
Figure 40. China Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Japan Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. South Korea Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Southeast Asia Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. India Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Australia Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Latin America Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Latin America Targeted Drugs for Breast Cancer Market Share by Country (2019-2030)
Figure 48. Mexico Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Brazil Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. Middle East & Africa Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 51. Middle East & Africa Targeted Drugs for Breast Cancer Market Share by Country (2019-2030)
Figure 52. Turkey Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 53. Saudi Arabia Targeted Drugs for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 54. Roche Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)
Figure 55. Teva Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)
Figure 56. Mylan Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)
Figure 57. Hikma Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)
Figure 58. Hengrui Medicine Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)
Figure 59. Cipla Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)
Figure 60. Reliance Group Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)
Figure 61. Hetero Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)
Figure 62. Pfizer Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)
Figure 63. Eli Lilly Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)
Figure 64. Novartis Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)
Figure 65. CANbridge Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)
Figure 66. Puma Biotechnology Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)
Figure 67. AstraZeneca Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)
Figure 68. Chugai Pharmaceutical Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)
Figure 69. Eisai Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)
Figure 70. GlaxoSmithKline Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)
Figure 71. Bristol-Myers Squibb Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)
Figure 72. Otsuka Pharmaceutical Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)
Figure 73. Merck Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)
Figure 74. BioMarin Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)
Figure 75. Hengrui Pharmaceutical Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)
Figure 76. Beijing Biostar Technologies Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)
Figure 77. Bayer Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2019-2024)
Figure 78. Bottom-up and Top-down Approaches for This Report
Figure 79. Data Triangulation
Figure 80. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
